18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
about
Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.PET/MRI for the evaluation of patients with lymphoma: initial observations.Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma.The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphomaState-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.Incorporating prognostic imaging biomarkers into clinical practice.Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma.ALK positive Anaplastic Large Cell Lymphoma of the Thoracic Spine.PET imaging for Treatment Response in CancerCurrent clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes.Whole-body diffusion-weighted imaging for staging malignant lymphoma in children.18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging.Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?Advances in oncologic imaging: update on 5 common cancers.ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).Predicting tumour response.Current role of FDG PET/CT in lymphoma.Role of PET in lymphoma.IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types.Evolution of lymphoma staging and response evaluation: current limitations and future directions.Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.FDG-PET in Follicular Lymphoma ManagementWhen 18-fluorodeoxyglucose-positron emission tomography is indeterminate, the International Prognostic Index is the answer.Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt?Assessment of the nature of residual masses at end of treatment in lymphoma patients using volume perfusion computed tomography.Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma.Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.Interim 18F-FDG PET/CT improves the prognostic value of S-IPI, R-IPI and NCCN-IPI in patients with diffuse large B-cell lymphoma.Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management.Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".Discussion of 18F-FDG PET/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma.Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
P2860
Q26781731-4B23B4C0-713D-4BF5-965F-DB7E15739CC8Q33606294-DFF9D565-E407-4803-B4B6-B26D38CB8202Q34355722-FA8BB456-149B-4842-B5E3-1F46E3F75A0EQ35737190-DC0E3943-87F5-471B-8131-970C178ABAE5Q36429831-BF71FBE9-841A-46D9-8589-C117E8D06620Q36747993-A8DC73A5-6482-46CB-BE8A-B2950E77B8B0Q37058257-378835AD-0085-4EF9-80C0-CB93EC17993FQ37144956-17290E9E-B823-4899-B9D2-77817BE454BBQ37149757-41C90BCF-4C6A-4F25-B442-904CE26FCCE8Q37193816-6862947B-9303-4962-AB9A-1DC417CA1221Q37307649-502A8590-DAB5-46F0-A9D1-B3BB79B6B4E4Q37341368-5393057A-87CC-48A0-9BF7-7C060B9E014DQ37465205-836513AA-1EAD-42C0-A4EB-9A79047F961DQ37622870-135E6883-01BB-47FA-A634-C37F34040184Q37777048-27A59B56-10E1-47F5-A46C-0394E745B8C0Q37789665-B12D6C3E-8215-4FAA-9FAF-D3D5224AD8C8Q38020234-048BC1F3-2112-4A5F-9118-C93566C675A0Q38020791-233C0DE4-3113-4F62-A82B-CFD55D66AA44Q38052458-1C3E5201-C7BD-4C99-9E64-E00953C46370Q38061883-9CB73BBF-580C-4839-9B0C-B846FECCBD9BQ38141699-46DE1471-CB5A-4CF8-A85D-EDFB36A109A5Q38187365-45F102BF-4729-43CC-B418-90E630A14229Q38195220-F702F8C4-7657-4B38-8ECF-C62AA875C2F1Q38523971-2722D2D7-82E0-417E-805C-18B432F855B9Q38671671-80A04F18-F719-43A7-AE63-69DF0F1B875FQ40616101-2DD08468-D51E-4103-A620-C5B1B95611F1Q41840128-3421790E-FF5B-42D9-845C-718E360A35BEQ43109648-48B254B7-B67D-40CF-8FB0-5E876AD29CEEQ43188726-B63E111A-A5D7-43E3-9A1E-369550F5E5C9Q45327942-705B46F7-9637-4C84-8F20-F3D42568A418Q46792873-4FF467DA-EF19-4F50-9E11-C88E74343573Q48330706-545FD4B2-7E55-419A-A11F-C919330FC548Q48516167-1383BFCE-D1BB-4EB6-9EBE-0E6983503327Q49486010-FD4C5D64-ED3D-4F08-AE05-DA28111F27F0Q52937933-CF5154E2-C36A-469B-A6B7-A142CFCB8ED2Q52965516-74F50AB1-586F-40F1-831C-FE9847A77D0CQ53235861-42917136-44DC-4394-A7B6-DF8724E0E3D5
P2860
18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
18F-FDG PET for posttherapy as ...... lymphoma: a systematic review.
@en
18F-FDG PET for posttherapy as ...... lymphoma: a systematic review.
@nl
type
label
18F-FDG PET for posttherapy as ...... lymphoma: a systematic review.
@en
18F-FDG PET for posttherapy as ...... lymphoma: a systematic review.
@nl
prefLabel
18F-FDG PET for posttherapy as ...... lymphoma: a systematic review.
@en
18F-FDG PET for posttherapy as ...... lymphoma: a systematic review.
@nl
P2093
P1476
18F-FDG PET for posttherapy as ...... lymphoma: a systematic review.
@en
P2093
Hirokazu Nagai
Takashi Nihashi
Teruhiko Terasawa
Tomomitsu Hotta
P356
10.2967/JNUMED.107.039867
P407
P577
2007-12-12T00:00:00Z